Vesicular Stomatitis Virus Expressing Tumor Suppressor p53 Is a Highly Attenuated, Potent Oncolytic Agent
Authors:
- 15 October 2011
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (20) , 10440-10450
Abstract
Vesicular stomatitis virus (VSV), a negative-strand RNA rhabdovirus, preferentially replicates in and eradicates transformed versus nontransformed cells and is thus being considered for use as a potential anticancer treatment. The genetic malleability of VSV also affords an opportunity to develop more potent agents that exhibit increased therapeutic activity. The tumor suppressor p53 has been shown to exert potent antitumor properties, which may in part involve stimulating host innate immune responses to malignancies. To evaluate whether VSV expressing p53 exhibited enhanced oncolytic action, the murine p53 (mp53) gene was incorporated into recombinant VSVs with or without a functional viral M gene-encoded protein that could either block (VSV-mp53) or enable [VSV-M(mut)-mp53] host mRNA export following infection of susceptible cells. Our results indicated that VSV-mp53 and VSV-M(mut)-mp53 expressed high levels of functional p53 and retained the ability to lyse transformed versus normal cells. In addition, we observed that VSV-ΔM-mp53 was extremely attenuated in vivo due to p53 activating innate immune genes, such as type I interferon (IFN). Significantly, immunocompetent animals with metastatic mammary adenocarcinoma exhibited increased survival following treatment with a single inoculation of VSV-ΔM-mp53, the mechanisms of which involved enhanced CD49b + NK and tumor-specific CD8 + T cell responses. Our data indicate that VSV incorporating p53 could provide a safe, effective strategy for the design of VSV oncolytic therapeutics and VSV-based vaccines.Keywords
This publication has 65 references indexed in Scilit:
- Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia ProteinCancer Cell, 2010
- Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapyCancer Gene Therapy, 2010
- Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse modelsGynecologic Oncology, 2010
- Adoptively transferred effector cells derived from naïve rather than central memory CD8+T cells mediate superior antitumor immunityProceedings of the National Academy of Sciences, 2009
- Inflammation and Cancer: IL-6 and STAT3 Complete the LinkCancer Cell, 2009
- Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisProceedings of the National Academy of Sciences, 2008
- Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2008
- A microRNA component of the p53 tumour suppressor networkNature, 2007
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon inductionNature Immunology, 2005